Use of prostaglandins and bromocriptine mesylate for pregnancy termination in bitches

Gobello, Cristina; Castex, Gervasio; Corrada, Yanina Alejandra; Klima, Liliana; Sota, Rodolfo Luzbel de la; Rodríguez, Raúl Ricardo

doi:10.2460/javma.2002.220.1017

Cited by 15 publications

(4 citation statements)

References 9 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with dopamine agonists that exert antiprolactinergic effect via stimulation of D2 pituitary receptors or inhibition of central serotoninergic receptors from day 35 to 40 can result in abortion (Concannon and others 1987, Post and others 1988, Onclin and others 1993). There are also other methods of terminating pregnancy such as combining prostaglandins and dopamine agonists, studies of which have shown good results and fewer side effects (Onclin and others 1993, Onclin and others 1995, Onclin and Verstegen 1996, Gobello and others 2002). Dexamethasone has also been used to terminate pregnancy in bitches (Zone and others 1995, Wanke and others 1997).…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of mid‐term pregnancy termination using aglepristone in dogs

Pettersson¹,

Tidholm²

2009

J of Small Animal Practice

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of mid‐term pregnancy termination using aglepristone in dogs

Pettersson¹,

Tidholm²

2009

J of Small Animal Practice

View full text Add to dashboard Cite

“…Safe and applicable methods consisting of inexpensive pharmacological agents for abortion are particularly desired. The administration of different abortifacients such as, prostaglandin F2α, dopamine agonists, dexamethasone and progesterone blockers were tested at different doses, alone or in combination for mid-gestation pregnancy termination in dogs (Kaya et al, 2014;Petterson and Tidholm, 2009;Galac et al, 2000;Cetin et al, 2000;Corrada et al, 2006;Hori et al, 2002;Gobello et al, 2002;Onclin and Verstegen, 1999;Feldman et al, 1993;Shille et al, 1984;Wanke et al, 1997;Zone et al, 1995;Onclin and Verstegen, 1996). Great oxygen consumption by feto-maternal unit and alterations in metabolic pathways are the reasons of increased oxidative stress during pregnancy period, leading imbalance between the formation of free radicals and the capacity for defense of the antioxidant mechanisms (Harma et al, 2004;Casanueva and Viteri, 2003;Vannucchi et al, 2007;Krieger and Loch-Caruso, 2001).…”

Section: Introductionmentioning

confidence: 99%

Oxidative stress in dogs during mid-gestation abortion: Fetal and maternal antioxidant alterations with clinical and hematological features

Özalp¹,

Gül²,

Seyidoglu³

et al. 2022

J Hellenic Vet Med Soc

View full text Add to dashboard Cite

The present study aimed to evaluate the GSH and MDA levels in dog’s serum and vital organs of aborted fetuses, after application of two abortifacient. Animals of group I (n = 6) were treated twice with subcutaneous injection of 10 mg/kg aglepristone and group II (n = 3) received prostaglandin F2α at a dose of 125 μg/kg every 12 hours until abortion process completed. Hematologic examinations and sedimentation rates were performed of bitches. The duration between first occurrence of vaginal discharge to first expulsion of fetuses ranged between 14-29 hours (mean: 22.6±5.5 h) and 24-33 hours in group I and II, respectively. Both treatments significantly increased the serum MDA levels (P<0.01); however aglepristone increased the MDA levels throughout the study, prostaglandin enhanced plasma MDA levels only on day 1. GSH levels were significantly lower in aglepristone-treated bitches than prostaglandin-treated animals (P<0.05). The treatments resulted similar MDA levels in liver and heart tissues (P>0.05). GSH levels in kidney, muscle and heart tissues did not differ between groups (P>0.05), aglepristone resulted reduced GSH levels in liver tissue (P<0.05). High MDA levels could be evaluated as a useful marker for fetal suffering in pregnancy controls. The MDA and GSH levels, measured in vital organs of fetuses, could suggest possible toxic effects of abortifacients in newborns, as both medical agents are being used in parturition induction.

show abstract

“…This association allows to reduce PG dosage and consequently the intensity of the PG side effects (Onclin and Verstegen 1996, 1999; Aslan et al. 2001; Gobello et al. 2002).…”

Section: Introductionmentioning

confidence: 99%

Partial Foetal Retention Following Aglepristone Treatment in a Bitch

Rigau

Rodríguez‐Gil

García

et al. 2010

Reprod Domestic Animals

View full text Add to dashboard Cite

This short communication describes the case of partial foetal retention in an 18-month-old female French bulldog following induction of abortion owing to an undesired mating. Abortion was induced with aglepristone administered in two consecutive protocols of a dual injection 1 day apart. After failure of the first treatment to achieve abortion, 15 days later, a second treatment was administered. Delivering of aborted foetus occurred 2 days after the last administration. Five weeks after the abortion, the female showed a weak haemorrhagic vaginal discharge. On ultrasound examination, the presence of uterine wall distension as well as a puppy skull inside the uterus was observed. This clinical case makes clear that although aglepristone is a very reliable drug, follow-up of the female during treatment and in the immediate post-partum is necessary to ensure a good outcome.

show abstract

Use of prostaglandins and bromocriptine mesylate for pregnancy termination in bitches

Cited by 15 publications

References 9 publications

Safety and efficacy of mid‐term pregnancy termination using aglepristone in dogs

Safety and efficacy of mid‐term pregnancy termination using aglepristone in dogs

Oxidative stress in dogs during mid-gestation abortion: Fetal and maternal antioxidant alterations with clinical and hematological features

Partial Foetal Retention Following Aglepristone Treatment in a Bitch

Contact Info

Product

Resources

About